A strategic collaboration has been formed between 4D pharma and The University of Texas MD Anderson Cancer Center, which is aimed at evaluating 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.
Combining MD Anderson’s translational medicine and clinical research capabilities with 4D’s expertise in the discovery and development of live biotherapeutics, the alliance will initially assess MRx0518, which is 4D’s lead oncology candidate, as a potential treatment for solid tumors. The first clinical study will evaluate MRx0518 in combination with Keytruda and will be performed in collaboration with Merck.
Additionally, further studies, including the evaluation of MRx0518 in combination with sterotactic body radiotherapy for the treatment of pancreatic cancer, are planned under the collaboration between 4D and MD Anderson.
This alliance will provide a strong and long-term foundation for the development of 4D’s Live Biotherapeutics in cancer. The current study, which will be one of the first live biotherapeutic programs to reach the clinic in the immuno-oncology space, represents an important step forward in the development of MRx0518 and 4D’s broader oncology franchise. We look forward to continuing to work with our partners at MD Anderson to progress this study and help bring this therapy to patients.
commented Duncan Peyton, 4D’s chief executive officer.
Live biotherapeutics employ strains of gut bacteria that have been isolated from healthy human donors, and which are encapsulated, administered orally and delivered to the gut as a therapeutic. Each strain is selected for its functionality to perform a specific role in combatting a disease.
MD Anderson is focused on providing the best possible care for cancer patients, including implementing the latest new treatment modalities,” “The gut microbiome has emerged as an important next-generation target in cancer therapy, and we hope that live biotherapeutics will have the potential to make a significant difference for patients across a range of cancers.
said Shubham Pant, MBBS, associate professor
of Investigational Cancer Therapeutics at MD Anderson.